Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 9/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.36 |
| ▸ | MAOB | P27338 | 3/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PRF1 | P14222 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22718951 | 1.00 | KCNJ1 (0.66) | KCNJ1KCNH2MAOBMAOALMNA | |
| SCHEMBL286426 | 0.85 | KCNJ1 (0.51) | KCNJ1KCNH2MAOBMAOALMNA | |
| SCHEMBL16836137 | 0.79 | KCNJ1 (1.00) | KCNJ1KCNH2LMNAACHESSTR1 | |
| SCHEMBL29567627 | 0.79 | KCNJ1 (1.00) | KCNJ1KCNH2LMNAACHESSTR1 | |
| SCHEMBL11453548 | 0.78 | KCNJ1 (0.64) | KCNJ1KCNH2MAOBMAOALMNA | |
| SCHEMBL854575 | 0.78 | KCNJ1 (0.46) | KCNJ1KCNH2MAOBMAOALMNA | |
| SCHEMBL4549443 | 0.76 | KCNJ1 (0.45) | KCNJ1KCNH2MAOBMAOALMNA | |
| SCHEMBL286755 | 0.75 | KCNJ1 (0.44) | KCNJ1KCNH2MAOBMAOALMNA | |
| SCHEMBL2733555 | 0.75 | KCNJ1 (0.44) | KCNJ1KCNH2MAOBMAOALMNA | |
| SCHEMBL855133 | 0.75 | KCNJ1 (0.44) | KCNJ1KCNH2MAOBMAOALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976027-B1 | QUINOLINE DERIVATIVES AS FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12304899-B2 | Factor XI activation inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-05-20 | — | — | US | disclosed |
| US-20220235033-A1 | FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-07-28 | — | — | US | disclosed |
| EP-3976027-A1 | FACTOR XI ACTIVATION INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12304899-B2 | Factor XI activation inhibitors | F11, TFPI, F13B | KCNJ1 2770/4885KCNH2 2681/4885MAOB 312/4885 |
| US-20220235033-A1 | FACTOR XI ACTIVATION INHIBITORS | F11, TFPI, F13B | KCNJ1 2770/4885KCNH2 2681/4885MAOB 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.